Episodes
6 days ago
6 days ago
Identifying and addressing the social determinants of health (SDOH) influences health outcomes and can positively impact health equity in our society. While health systems in the US are screening for SDOH more often, information on how to improve screening efficiency and effectiveness is lacking. A recently published study was designed to determine what patient and clinician factors are associated with early implementation of SDOH screening in primary care.
Guest Author: Sharmon P. Osae, PharmD, BCACP, CDCES
Music by: Good Talk
Friday Mar 29, 2024
Treating Depression and Anxiety: Dosing, Pharmacogenetics, and Our Learners
Friday Mar 29, 2024
Friday Mar 29, 2024
This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org.
Mental illness is very common - 1 in 5 adults in the United States will have a mental illness during their lifetime. Every ambulatory care (and community) pharmacist should be confident in their ability to recognize mental health challenges and how to use medications in an optimal manner to treat them. This is a FOLLOW-UP conversation from the ACCP Annual Meeting program entitled Ambulatory Care PRN Focus Session — Breaking Down Depression and Anxiety Management for the Ambulatory Care Pharmacist.
Expert Panelists: Richard Silvia, PharmD, BCPP and Jordan Baye, PharmD, BCPS
Music by lemonmusicstudio from Pixabay
Friday Mar 29, 2024
Complex Patient Case 4: Diabetes, CKD, and Psoriasis
Friday Mar 29, 2024
Friday Mar 29, 2024
Reason for Visit: Referred by primary care provider to pharmacy services for education and management; diabetes not responding to oral therapy.
Guest Authors: Jillian Cerullo, PharmD and Michelle Gauvin, PharmD, BCACP, BCGP, CDCES
Expert Panelists: Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM and Joshua Neumiller, PharmD, CDCES
Music by Good Talk
Friday Mar 15, 2024
Friday Mar 15, 2024
Weight extremes, a body-mass index (BMI) either very underweight or obese, are associated with increased all-cause mortality. Mortality attributable to obesity is caused by many secondary conditions like metabolic disorders and cardiovascular (CV) disease. Enter the glucagon-like peptide-1 (GLP-1) receptor agonists—initially approved in the treatment of type 2 diabetes— which induce significant weight loss regardless of diabetes status. But can a weight loss drug decrease CV mortality?
Guest Authors: Gregory Castelli, PharmD, BCPS, BC-ADM, CDCES and Drake Meaney, PharmD, BCPS
Music by Good Talk
Saturday Mar 02, 2024
Saturday Mar 02, 2024
Pharmacists are the most accessible health professionals and can play a vital role in screening and managing hypertension. But would an expanded scope of practice that enabled pharmacists to prescribe and manage antihypertensive therapies be cost-effective?
Guest Authors: Stefania Cian, PharmD and Candice Garwood, PharmD, FCCP, BCPS, BCACP
Special Guest: Dave Dixon, PharmD, BCACP, CLS
Music by Good Talk
Friday Feb 16, 2024
Heartburn Headache: Cumulative PPI Use and Dementia Risk
Friday Feb 16, 2024
Friday Feb 16, 2024
Omeprazole ranks among the top 10 most prescribed medications in the United States, and many patients take proton pump inhibitors (PPIs) for years. Widespread PPI use persists despite data about potential serious adverse effects. Some worry that PPI use increases the risk of dementia. Are those worries supported by data?
Guest Authors: Molly M. Corder, PharmD, BCPS, BCACP and Ryan S. Ades, PharmD, BCPS
Music by Good Talk
Friday Feb 02, 2024
Friday Feb 02, 2024
Most clinical settings now use oscillometric BP devices to measure patients’ BP, and over half of people with hypertension (HTN) use a home BP monitor. Can we trust these BP readings if an inappropriate cuff size was used? How will this impact the way we assess BP control?
Guest Authors: Vincent Lam, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP, CDCES
Music by Good Talk
Friday Jan 19, 2024
Friday Jan 19, 2024
Over 75% of heart failure with preserved ejection fraction (HFpEF) patients have a comorbid diagnosis of obesity. Obesity is an independent risk factor for the development of HFpEF and contributes to disease progression. Obese patients with HFpEF have greater symptom burden, reduced functional capacity, and impaired quality of life when compared to those without obesity. We know that patients often struggle to adhere to lifestyle modifications long enough to see meaningful weight loss, but the benefits of GLP-1 agonists for patients with HFpEF who are obese are not yet clear.
Guest Authors: Alicia M. Nordberg-Payne, PharmD; Rebecca Munger, PharmD, BCACP; Jason Zupec, PharmD, BCACP
Music by Good Talk
Saturday Jan 06, 2024
Do Statins “REPRIEVE” People Living with HIV from CV Events?
Saturday Jan 06, 2024
Saturday Jan 06, 2024
As people living with HIV age, the risk of cardiovascular disease becomes the greatest threat to their health and quality of life. Not only does inflammation from HIV infection contribute to atherosclerotic cardiovascular disease (ASCVD), but dyslipidemia from the antivirals commonly used to treat HIV further enhances that risk. But does statin therapy reduce ASCVD risk in patients living with HIV? That's the question that the REPRIEVE study attempted to answer.
Guest Authors: Laura Lerner, PharmD and Joseph Nardolillo, PharmD, BCACP
Music by Guest Talk
Sunday Dec 17, 2023
Top Ten Things Every Clinician Should Know About the RSV Vaccines
Sunday Dec 17, 2023
Sunday Dec 17, 2023
Respiratory syncytial virus (RSV) is a common respiratory virus that typically causes mild cold-like symptoms but can potentially cause severe illness in children and older adults. Every year, thousands of older adults and infants are hospitalized due to RSV, and 10,000 or more die. In 2023, two vaccines (Abrysvo and Arexvy) and a monoclonal antibody (Beyfortus) became available to help prevent lower respiratory tract disease (LRTD) associated with RSV.